Search research articles
Contact Us
Filters
Showing results (91-100 of 179) with videos related to
Page
of 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
British Journal of Cancer
|
April 4, 2024
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
Terufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Research Square
|
May 27, 2024
Joint multi-omics discriminant analysis with consistent representation learning using PANDA
Muhammad Aminu, Lingzhi Hong, Natalie Vokes, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
NPJ Precision Oncology
|
January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson
Jeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 179) with videos related to
Sort By:
Page
of 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
British Journal of Cancer
|
April 4, 2024
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
Terufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Research Square
|
May 27, 2024
Joint multi-omics discriminant analysis with consistent representation learning using PANDA
Muhammad Aminu, Lingzhi Hong, Natalie Vokes, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
NPJ Precision Oncology
|
January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson
Jeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Page
of 18